Disease Introduction
Acne, also known as pimples, is a chronic inflammation of the hair follicles and sebaceous glands. It is related to excessive sebum secretion, proliferation of Propionibacterium acnes, and inflammatory response. It commonly occurs on the face, chest, and back, and manifests as blackheads, red papules, pustules, and even nodules and cysts, which can leave acne marks and pits.
Cutting-edge high-precision diagnostic and treatment technologies
- New topical drug targeting androgens : Clacotene (clascoterone) is a topical androgen receptor inhibitor that locally inhibits sebum secretion with few systemic side effects; it has been approved for use in the United States for acne, and a 1% clascoterone cream is currently undergoing a Phase III bridging clinical trial in China (CTR20260489), and is expected to be launched soon.
- Narrow-spectrum oral new drug : sarecycline hydrochloride (trade name Liv) is a targeted narrow-spectrum tetracycline oral antibiotic. It was launched for pre-sale in China in August 2026. Compared with traditional broad-spectrum tetracyclines, it has less impact on the intestinal flora and a lower risk of drug resistance.
- Precision laser hair removal and sebum reduction : The 1726nm contact cooling laser (Aviclear) treats inflammatory acne by selectively thermally targeting the sebaceous glands, and the 2025 consensus recommends it for mild to moderate acne; new light sources such as the 577nm diode laser have also shown good efficacy.
- Topical PROTAC Degrading Agent : Kintor Pharmaceutical's GT20029 gel (the world's first topical AR-PROTAC degrading agent) met its primary endpoint in a Phase II clinical trial in China for the treatment of acne in August 2025, representing a new direction for topical precision targeted therapy.
